Oragenics Inc (OGEN)

$0.55 +0.00 (0.27%)
Market Cap 2.41M
Revenue (ttm) 0.00
Net Income (ttm) -9.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,905
Avg Vol 33,840
Day's Range N/A - N/A
Shares Out 4.51M
Stochastic %K 62%
Beta 1.24
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Address:
9015 Town Center Parkway, Suite 143, Lakewood Ranch, United States
Chillywilly_72
Chillywilly_72 Aug. 19 at 3:51 PM
$OGEN My head hurts and I cant think straight. I feel and hit my head on a table. I need some sort of drug to help remedy the swelling quickly. I need this ASAP!
0 · Reply
NMax
NMax Aug. 19 at 3:38 AM
$OGEN Racketjackass can suck a fat one. 😁 I'm adding!!! 🤑🤑🤑
0 · Reply
samuel99
samuel99 Aug. 19 at 2:38 AM
$OGEN check this out!! First of it's kind fusion engine. Company just got cleared uplist imminent. American Fusion Inc. (OTC: AMFN) Receives FINRA Clearance https://share.google/7U0LRD5B2PxpvilX0
1 · Reply
RocketQueen
RocketQueen Aug. 18 at 4:47 PM
$OGEN guaranteed money shredder....
0 · Reply
NMax
NMax Aug. 17 at 6:21 PM
$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 17 at 5:28 PM
$OGEN close to guaranteed failure here. Janet is already arranging for the next 1:50 or 1:60 reverse split I'm hoping this company gets sued into the next century for all of the money they've stolen from retail with nothing to show for it.
1 · Reply
stocks7253836
stocks7253836 Aug. 17 at 3:52 PM
$OGEN solid volume today but need more to run
1 · Reply
SXCross
SXCross Aug. 17 at 2:19 PM
$OGEN What`s going on today? news?
1 · Reply
NMax
NMax Aug. 17 at 1:31 PM
$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 17 at 2:12 AM
$OGEN https://firstwordpharma.com/story/5690162
0 · Reply
Latest News on OGEN
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Jul 7, 2026, 8:30 AM EDT - 6 weeks ago

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

May 19, 2026, 8:45 AM EDT - 3 months ago

Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21

ORAGENICS PROVIDES INVESTOR UPDATE

May 18, 2026, 8:30 AM EDT - 3 months ago

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 7, 2026, 8:30 AM EDT - 3 months ago

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

May 5, 2026, 8:30 AM EDT - 3 months ago

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

2026-04-20T14:01:13.000Z - 4 months ago

Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Apr 13, 2026, 8:30 AM EDT - 4 months ago

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics receives audit opinion with going concern explanation

2026-03-25T22:35:16.000Z - 5 months ago

Oragenics receives audit opinion with going concern explanation

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Mar 25, 2026, 6:30 PM EDT - 5 months ago

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Oragenics files annual report on Form 10-K

2026-03-17T12:49:42.000Z - 5 months ago

Oragenics files annual report on Form 10-K

Oragenics initiates Phase IIa clinical trial site activation

2026-03-12T12:48:45.000Z - 5 months ago

Oragenics initiates Phase IIa clinical trial site activation

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Mar 12, 2026, 8:30 AM EDT - 5 months ago

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Oragenics explores potential acquisition of additional assets in CNS space

2026-03-11T12:45:33.000Z - 5 months ago

Oragenics explores potential acquisition of additional assets in CNS space

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Mar 11, 2026, 8:30 AM EDT - 5 months ago

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

2026-03-10T12:42:00.000Z - 5 months ago

Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Oragenics previews targeted milestones for 2026

2026-02-09T13:46:12.000Z - 6 months ago

Oragenics previews targeted milestones for 2026

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Feb 9, 2026, 8:30 AM EST - 6 months ago

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

2026-02-03T13:40:46.000Z - 7 months ago

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Feb 3, 2026, 8:30 AM EST - 7 months ago

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Oragenics files $100M mixed securities shelf

2026-01-22T21:15:38.000Z - 7 months ago

Oragenics files $100M mixed securities shelf

Oragenics Q3 2025 Shareholder Update

Nov 12, 2025, 8:30 AM EST - 10 months ago

Oragenics Q3 2025 Shareholder Update

Oragenics regains compliance with NYSE

2025-10-21T12:15:12.000Z - 10 months ago

Oragenics regains compliance with NYSE

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics, Receptor.AI partner to accelerate pipeline development

2025-10-07T13:20:29.000Z - 11 months ago

Oragenics, Receptor.AI partner to accelerate pipeline development

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oct 7, 2025, 8:30 AM EDT - 11 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

2025-08-11T12:50:19.000Z - 1 year ago

Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.

Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 1 year ago

Oragenics Q2 2025 Shareholder Update

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

2025-07-31T12:52:03.000Z - 1 year ago

Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

2025-07-16T12:45:56.000Z - 1 year ago

Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 1 year ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Oragenics Completes Approximately $16.5 Million Offering

Why Is Oragenics Stock (OGEN) Down 55% Today?

2025-07-02T01:00:00.000Z - 1 year ago

Why Is Oragenics Stock (OGEN) Down 55% Today?

Oragenics trading resumes

2025-07-01T12:50:11.000Z - 1 year ago

Oragenics trading resumes

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

2025-07-01T12:41:48.000Z - 1 year ago

Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics trading halted, news pending

2025-07-01T12:05:53.000Z - 1 year ago

Oragenics trading halted, news pending

Oragenics trading resumes

2025-06-03T13:40:31.000Z - 1 year ago

Oragenics trading resumes

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 1 year ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 1 year ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 1 year ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 2 years ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 2 years ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 2 years ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 2 years ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 2 years ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 2 years ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 2 years ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 2 years ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 2 years ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 2 years ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 2 years ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 2 years ago

Oragenics Announces Pricing of Public Offering

Chillywilly_72
Chillywilly_72 Aug. 19 at 3:51 PM
$OGEN My head hurts and I cant think straight. I feel and hit my head on a table. I need some sort of drug to help remedy the swelling quickly. I need this ASAP!
0 · Reply
NMax
NMax Aug. 19 at 3:38 AM
$OGEN Racketjackass can suck a fat one. 😁 I'm adding!!! 🤑🤑🤑
0 · Reply
samuel99
samuel99 Aug. 19 at 2:38 AM
$OGEN check this out!! First of it's kind fusion engine. Company just got cleared uplist imminent. American Fusion Inc. (OTC: AMFN) Receives FINRA Clearance https://share.google/7U0LRD5B2PxpvilX0
1 · Reply
RocketQueen
RocketQueen Aug. 18 at 4:47 PM
$OGEN guaranteed money shredder....
0 · Reply
NMax
NMax Aug. 17 at 6:21 PM
$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 17 at 5:28 PM
$OGEN close to guaranteed failure here. Janet is already arranging for the next 1:50 or 1:60 reverse split I'm hoping this company gets sued into the next century for all of the money they've stolen from retail with nothing to show for it.
1 · Reply
stocks7253836
stocks7253836 Aug. 17 at 3:52 PM
$OGEN solid volume today but need more to run
1 · Reply
SXCross
SXCross Aug. 17 at 2:19 PM
$OGEN What`s going on today? news?
1 · Reply
NMax
NMax Aug. 17 at 1:31 PM
$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 17 at 2:12 AM
$OGEN https://firstwordpharma.com/story/5690162
0 · Reply
NMax
NMax Aug. 16 at 10:30 PM
$OGEN Yeah...so anyways... Continuing to accumulate!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 16 at 4:26 AM
$OGEN Oragenics, Inc. (OGEN) has a short interest of approximately 17.36% of its float, with roughly 781,000 shares sold short. Compared to the broader market where typical stocks maintain single-digit short interest under 5%, OGEN’s short interest is relatively high...--G, A
0 · Reply
NMax
NMax Aug. 14 at 1:15 PM
$OGEN Here we are years after you fellas claimed to have sold. Still trying to figure out how many shares I have. Begging me not to add. Making claims regarding investors that really shouldnt affect you in any way...if you sold. Pretty clear the accounts making those posts are part of the manipulation of this asset. So I'll just keep adding!! 🤑🤑🤑
0 · Reply
sincosine
sincosine Aug. 14 at 9:09 AM
$OGEN dead stock with no value . Keep paying the scum bags management and the bastards that work for them. Keep pretending that you bought shares but show no proof. POS stock period absolutely 💯 no value!
1 · Reply
NMax
NMax Aug. 13 at 2:10 PM
$OGEN Careful. 😉 Continuing to accumulate!! Suck it!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 13 at 1:40 PM
$OGEN dangerous.
0 · Reply
NMax
NMax Aug. 12 at 4:41 PM
$OGEN Yeah...so anyways.. Adding, adding, adding!! Suck it!! 😂 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 12 at 3:12 PM
$OGEN best to sell before this starts trading at .20.
0 · Reply
NMax
NMax Aug. 11 at 10:55 PM
$OGEN Yeah...so anyways... Continuing to accumulate!!! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Aug. 11 at 2:02 PM
$OGEN sell the hype (if any) when they announce patient enrollment, it's going below .20 when the data is read out.
0 · Reply
RocketQueen
RocketQueen Aug. 10 at 8:12 PM
$OGEN best to get out when they reach full patient enrollment and data lock. It's going to drop like a stone once the results are read out.
0 · Reply
NeverTilted
NeverTilted Aug. 10 at 2:08 PM
$OGEN added. I like this stock
0 · Reply